Get started
Author

Enas A. Al-Hurani

Observed name: Enas A. Al‐Hurani
ORCID: 0000-0002-1501-1971
Observed ORCID: 0000-0002-1501-1971
OpenAlex ID: A5014474058
IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions
2025 · Raed M. Al-Zoubi, Mai Elaarag, et al. · Frontiers in Pharmacology · 36
PDF
Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
2023 · Mothana K. Al-Omari, Mai Elaarag, et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 35
PDF
Pim kinase inhibitors in cancer: medicinal chemistry insights into their activity and selectivity
2020 · Soraya Alnabulsi, Enas A. Al-Hurani · Drug Discovery Today · 31
Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design
2019 · Soraya Alnabulsi, Enas A. Al-Hurani, et al. · Journal of Molecular Graphics and Modelling · 16
Hit-to-lead optimization of amino-carboxamide benzothiazoles as LSD1 inhibitors
2023 · Du’a Al bustanji, Soraya Alnabulsi, et al. · Medicinal Chemistry Research · 2
Benzofuran‐Based Uricosuric Agents: History, Roles, and Challenges
2026 · Raed M. Al‐Zoubi, Basma Hanbali, et al. · ChemistrySelect · 1
The rise of selective estrogen receptor modulators (SERMs) in breast cancer therapy: a promising horizon
2026 · Raed M. Al-Zoubi, Khalil Garada, et al. · Cancer Treatment and Research Communications · 1
Works count: 8
Citation count: 122
H-index: 4
I10-index: 4
Year
Topic
Type